Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.
Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.
In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.
The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.
Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.
Selecta Biosciences (NASDAQ: SELB) and Sobi announced positive topline results from the Phase 3 DISSOLVE I & II clinical trials for SEL-212, targeting chronic refractory gout. DISSOLVE I demonstrated a 56% response rate with 0.15 mg/kg SEL-212, while DISSOLVE II reported a 47% response rate. Among patients aged 50+, the response rate was 65% in DISSOLVE I and 48% in DISSOLVE II. Over 75% of patients in the extension phase remained responders at 12 months without safety signals. The favorable safety profile was noted with 3.4% experiencing infusion reactions. Regulatory submission for SEL-212 is expected in H1 2024.
Selecta Biosciences (NASDAQ: SELB) has reported its fourth quarter and full year 2022 financial results, highlighting a cash position of $136.2 million as of December 31, 2022, sufficient to fund operations until mid-2024. The company anticipates topline data from the Phase 3 DISSOLVE trials for SEL-212 in chronic refractory gout in Q1 2023. Selecta is also enrolling patients in the Phase 1/2 trial for SEL-302, targeting methylmalonic acidemia. The company's 2022 revenue reached $110.8 million, driven by collaborations, while net income for the year was $35.4 million, a significant improvement from the previous year.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for March 2, 2023, at 8:30 a.m. ET, to discuss its financial results for the fourth quarter and full year ending December 31, 2022. The call will provide insights into the company's financial performance and business updates, supported by the ImmTOR™ platform aimed at developing tolerogenic therapies for autoimmune diseases and gene therapies. Interested parties can join the call via phone or access the archive through the company's website.
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm, has announced participation in the SVB Securities Global Biopharma Conference, with a corporate update scheduled for February 14, 2023, at 8:00 a.m. ET. The conference will take place virtually, allowing one-on-one investor meetings. Selecta focuses on its ImmTOR™ platform, developing therapies for autoimmune diseases and gene therapies.
For further details, interested parties can access an archived webcast on the company’s website. Selecta has multiple programs aimed at enzyme and gene therapies, emphasizing its role in enhancing biologic therapy efficacy.
Selecta Biosciences (NASDAQ: SELB) provided an update on its 2023 roadmap, highlighting key milestones and partnerships. The company expects topline data from the Phase 3 DISSOLVE I & II programs for SEL-212 in chronic refractory gout in Q1 2023. Selecta also secured a $10 million upfront payment for a licensing deal for Xork, its IgG protease candidate, in collaboration with Astellas Gene Therapies for Pompe disease. Additionally, Selecta has selected an IL-2 development candidate and initiated the Phase 1/2 trial for SEL-302, aimed at treating methylmalonic acidemia.
Selecta Biosciences and Astellas Pharma have signed a licensing agreement for Xork, a next-generation IgG protease candidate aimed at enhancing the efficacy of Astellas’ AT845 gene therapy for Late-Onset Pompe Disease (LOPD). Selecta will receive a $10 million upfront payment and can earn up to $340 million in additional milestone payments, plus royalties on commercial sales. This collaboration aims to overcome patient eligibility issues in gene therapy trials due to pre-existing antibodies against AAV.
On December 14, 2022, Selecta Biosciences (NASDAQ: SELB) announced the selection of a next-generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program. This autoimmune disease leads to chronic kidney complications, and the newly selected protease aims to enhance renal dysfunction markers and reduce anti-drug antibodies (ADAs). The initiative involves a payment of $1.6 million to IGAN Biosciences. Selecta's innovative ImmTOR platform is thought to potentially address IgAN's underlying pathophysiology, providing valuable insights for future autoimmune disease treatments.
Selecta Biosciences (NASDAQ: SELB) has appointed Blaine Davis as Chief Financial Officer, effective November 28, 2022. Davis brings over 25 years of experience in biopharmaceutical finance and business development, having previously served as CFO at Protara Therapeutics. Selecta is on track for significant milestones in its pipeline, including a Phase 3 readout in chronic refractory gout and a Phase 1/2 trial in methylmalonic acidemia. Davis's expertise is expected to enhance the company's commitment to delivering long-term shareholder value and advancing its innovative ImmTOR™ platform.
WATERTOWN, Mass., Nov. 07, 2022 – Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company, will present at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day in New York from November 14-15, 2022. The company emphasizes its ImmTOR® platform, which aims to develop tolerogenic therapies for autoimmune diseases and enhance gene therapy effectiveness. The presentation is scheduled for November 14 at 1:35 p.m. ET, and investors can view a webcast on the company’s website.
Selecta Biosciences (NASDAQ: SELB) reported its Q3 2022 financial results, revealing a net loss of $7.9 million, down from $17.9 million in Q3 2021. As of September 30, Selecta had $148 million on hand, providing a financial runway into mid-2024. The company is on track to present joint topline data from DISSOLVE studies of SEL-212 for chronic refractory gout in Q1 2023 and initiate a Phase 1 trial for SEL-302 by Q4 2022. Collaboration and license revenue fell to $20.7 million compared to $24.4 million year-over-year.
FAQ
What is the market cap of Selecta Biosciences (SELB)?
What does Selecta Biosciences, Inc. specialize in?
What is SEL-212?
What is the significance of SVP™ technology?
What are the current projects in Selecta's pipeline?
What recent achievements has Selecta Biosciences made?
What partnerships does Selecta Biosciences have?
What is SEL-403?
How does Selecta Biosciences address risks in clinical trials?
What are the potential applications of Selecta's gene therapy candidates?
What are the key developments in Selecta's latest news?
